UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 22, 2008
AMAG PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
0-14732 |
| 04-2742593 |
(Commission File Number) |
| (IRS Employer Identification No.) |
|
|
|
100 Hayden Avenue |
|
|
Lexington, Massachusetts |
| 02421 |
(Address of principal executive offices) |
| (Zip Code) |
(617) 498-3300
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As of December 19, 2008, Jerome Lewis, the Senior Vice President of Scientific Operations of AMAG Pharmaceuticals, Inc. (the “Company”), has transitioned from an executive to an employee in an advisory capacity.
Item 8.01. Other Events.
On December 22, 2008, the Company issued a press release announcing that it has received a complete response letter from the U.S. Food and Drug Administration (“FDA”) for ferumoxytol for the treatment of iron deficiency anemia in chronic kidney disease patients. The press release, dated December 22, 2008, is attached as Exhibit 99.1 hereto and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The Company hereby files the following exhibit:
99.1 |
| Press Release dated December 22, 2008. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| AMAG PHARMACEUTICALS, INC. | |
|
| |
| By: | /s/ Joseph L. Farmer |
|
| Joseph L. Farmer |
|
| General Counsel and Senior Vice |
|
| President of Legal Affairs |
|
| |
|
| |
Date: December 23, 2008 | ||
3
EXHIBIT INDEX
Exhibit Number |
| Description |
99.1 |
| Press Release dated December 22, 2008. |
4